QuidelOrtho
QuidelOrtho Corporation, a leading player in the diagnostics industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1979, the company has achieved significant milestones, including the merger of Quidel Corporation and Ortho Clinical Diagnostics, which enhanced its market position and product offerings. QuidelOrtho specialises in innovative diagnostic solutions, focusing on areas such as infectious disease testing, women's health, and blood typing. Their core products, including rapid diagnostic tests and laboratory instruments, are distinguished by their accuracy and speed, catering to the evolving needs of healthcare providers. With a strong commitment to quality and innovation, QuidelOrtho has established itself as a trusted name in the diagnostics sector, recognised for its contributions to improving patient outcomes globally.
DitchCarbon Score
How does QuidelOrtho's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
QuidelOrtho's score of 30 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
QuidelOrtho's reported carbon emissions
In 2023, QuidelOrtho reported total carbon emissions of approximately 22,544,000 kg CO2e for Scope 1 and about 29,690,000 kg CO2e for Scope 2 (market-based). This represents a reduction in Scope 1 emissions from 26,212,000 kg CO2e in 2022, indicating a commitment to lowering their direct emissions. However, their Scope 2 emissions increased from approximately 28,369,000 kg CO2e in 2022. QuidelOrtho has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on transparency in its emissions reporting, with both Scope 1 and Scope 2 emissions disclosed. As a leading organisation in the diagnostics industry, QuidelOrtho's efforts reflect a growing awareness of the importance of climate commitments in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 26,212,000 | 00,000,000 |
| Scope 2 | 28,369,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
QuidelOrtho is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
